Bayer claims cell and gene therapy first in Parkinson’s research0 SHARESPosted: 23 September 2025 | Catherine Eckford (European Pharmaceutical Review) |Advances cell therapy and gene therapy candidates, with both showing neurorestorative potential against the disease. Cell therapy bemdaneprocel (BRT-DA01) and gene therapy AB-1005 are being developed in collaboration with Bayer’s subsidiary companies BlueRock Therapeutics and AskBio, respectively. Bemdaneprocel has moved into late-stage clinical trials and phase II studies of AB-1005 have also commenced, moves that make Bayer the first company to advance a cell therapy as well as a gene therapy against Parkinson’s disease, the firm said. Advancing gene therapy for Parkinson’sAdditionally, the first European participants have entered the phase II REGENERATE-PD clinical trial investigating AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, which is delivered intraputaminally. Last week, Bayer announced it has begun construction of a new cell and gene therapy centre in Berlin, Germany.